Press Releases

 Filter by Provider

HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE:LYB) today announced updates to its 2030 climate and circularity goals amid the need for disciplined capital allocation, evolving market conditions and regulatory developments. The goals remain ambitious, while balancing the need to adjust for near-term achievability. The company’s three-pillared strategy remains unchanged: growing and upgrading the core, building a profitable circular and low-carbon business, and stepping up performance and culture. To ensure alignment with the strategy and reflect the realities of today’s operating environment, the updated goals are as follows:

Company also names Jared Vichengrad to lead Axonius Federal Systems; appointments mark the culmination of a strategic leadership expansion amidst record-breaking financial results

CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has served on the board of several private and public healthcare companies including SeaSpine, Coherus BioSciences, Ob Hospitalist Group and most recently, VytlOne.

ORANGE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the Leerink Partners Global Healthcare Conference in Miami, Florida, on Tuesday, March 10, at 3:40 p.m. EST.

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences:

DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized.

Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU

Joint team will complete preliminary design of the GEK1500 engine to meet high performance and aggressive cost targets, leveraging GEK800 maturation to accelerate delivery

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:

LONDON and CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that Lance Baldo, M.D., Chief Executive Officer of Beacon Therapeutics and other members of the management team, will participate in TD Cowen's 46th Annual Health Care Conference being held March 2-4, 2026 in Boston, MA.

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March:

Enrollment Opens Nationwide for Full-Day, All-Summer Wondercamp

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025.

Wealth Management Data Infrastructure Leader Adds Veteran Orion Executive to Drive Operational Excellence and Client Success

Through the new capability Mod Op is enabling companies to monitor and mitigate brand-related risks from generative AI

Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado.

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Getty Images Holdings, Inc. (NYSE: GETY) (“Getty Images”) and Shutterstock, Inc. (NYSE: SSTK) announced today that the United States Department of Justice (DOJ) has concluded its review of the companies’ proposed merger of equals and the applicable waiting period under the Hart-Scott-Rodino Act has expired, without conditions.

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced that Geoff McDonough, M.D., Chief Executive Officer of NodThera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held February 25-26, 2026, in a virtual format.

Vancouver, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1; OTC:TEBAF) is pleased to announce further high-grade assay results from the Phase III drill campaign at the Cumavici Ridge polymetallic, epithermal vein zone within its principal Viogor-Zanik project in eastern Bosnia and Herzegovina.

ALBUQUERQUE, N.M., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies, Inc. (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology and fixed-tilt products, foundation solutions, software systems and services, today announced that members of its senior management team are scheduled to participate in the following conference for the investor community.

LAS VEGAS, Feb. 23, 2026 (GLOBE NEWSWIRE) -- VenHub Global, Inc. (NASDAQ: VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced a major advancement in its next-generation robotic systems that enhances reliability, safety, and operational continuity for the Company’s network of automated retail hubs.

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation in one-on-one meetings with investors at the TD Cowen 46th Annual Health Care Conference being held from March 2-4 in Boston.

Academy Securities, the nation’s first Post-9/11 veteran owned and operated investment bank, today announced the addition of Vice Admiral David H. Buss to its Geopolitical Intelligence Group. The Academy GIG consists of 39 US and UK Admirals & Generals, former NASA Astronauts, and former CIA/FBI Leadership. Academy has been advising clients for over a decade and is the preeminent Advisory on geostrategic risk to the markets.

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading provider of quantum computers.

KNOREX Ltd. (NYSE American: KNRX) ("KNOREX" or the "Company"), a leading provider of AI-driven programmatic advertising solutions, today announced results from a large-scale automotive campaign demonstrating how its unified AI-powered XPO platform converts national digital awareness campaigns into dealership visits at scale.

AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, will hold a conference call on Thursday, March 5, 2026 at 8:30 a.m. Eastern time to discuss its results for the third quarter of fiscal year 2026 ended December 31, 2025. Virtuix will also provide updates on joining the Made for Meta program enabling Omni One’s compatibility with Meta Quest headsets and games, recent expansion of Omni One sales to Europe, integration of AI-driven Gaussian splatting technology into its Virtual Terrain Walk (VTW) system, and other initiatives and anticipated milestones. A press release detailing these results will be issued prior to the call.

LOS GATOS, CA / ACCESS Newswire / February 23, 2026 / Atomera Incorporated ("Atomera" or the "Company") (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 5,000,000 shares of common stock, at an offering price of $5.00 per share, in a registered direct offering, for expected gross proceeds of approximately $25 million before placement agent fees and other offering expenses payable by Atomera. The offering is expected to close on or about February 24, 2026, subject to customary closing conditions.

AMC Entertainment Holdings, Inc. (NYSE: AMC) (the “Company,” or “AMC”), announced today that Muvico, LLC, a wholly-owned indirect subsidiary of AMC, has commenced an offering of $1,730 million aggregate principal amount of first lien notes due 2031 (the “Notes”) in a private offering (the “Offering”), subject to market and other conditions. The Notes will be guaranteed on a joint and several basis by the Company and each of its existing and future direct or indirect wholly-owned subsidiaries that guarantee obligations under the Company’s new $750 million term loan facility (the “New Term Loan Facility”) which is expected to be entered into concurrently with consummation of the Offering. The net proceeds from the Offering, together with the proceeds from the New Term Loan Facility, and cash on hand, will be used to (i) fund the redemption in full of $400 million aggregate principal amount of 12.750% Senior Secured Notes due 2027 (the “Odeon Notes”) issued by Odeon Finco PLC (“Odeon”), a wholly-owned direct subsidiary of Odeon Cinemas Group Limited and an indirect subsidiary of AMC, (ii) refinance the Company’s existing term loan facility in full, and (iii) pay related fees, costs, premiums and expenses in connection with such transactions.

AMC Entertainment Holdings, Inc. (NYSE: AMC) (“AMC” or “the Company”) today reported results for the fourth quarter and full year ended December 31, 2025, which have been posted to the Investor Relations section of AMC’s website at https://investor.amctheatres.com/.

Edu-Flex Innovations expanded its International Certification Indonesia programs by aligning professional credentials with AAPM, AAFM, and TÜV-related quality frameworks to support globally benchmarked competency development and workforce advancement.

NLO SMM announced the expansion of its digital marketing infrastructure platform, designed to support agencies and content creators with campaign management tools, analytics resources, and structured social media workflow solutions.

Partnership with Bruce ATS enables access to U.S. equities during Asia and Middle East business hours

Two new mineralized zones were discovered at Koela on the Igab project.Koela West highlights include trenches IGBT25-066 intersecting 11.0 m...

Potomac, Maryland--(Newsfile Corp. - February 23, 2026) - AI-powered software engineering company, Instinctools, has announced the expansion of its enterprise...

Starlab Space LLC, developer of a next-generation commercial space station, has successfully completed its Commercial Critical Design Review (CCDR) with NASA in attendance, marking a decisive transition from design to manufacturing and systems integration. The CCDR data supports the 28th milestone on the NASA Commercial LEO Destinations Space Act Agreement.

ProCap Financial, Inc. (Nasdaq: BRR), the first publicly traded agentic finance firm, today announced it repurchased 148,241 shares of its common stock in the open market on Friday, February 20, 2026.

Stanley Martin Homes, LLC (“Stanley Martin”) and United Homes Group, Inc. (NASDAQ: UHG) (“United Homes”) today announced that they have entered into a definitive agreement under which Stanley Martin will acquire United Homes in an all-cash transaction that represents an enterprise value of approximately $221 million.

Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the residential, agtech, and infrastructure markets, today announced that it has sold its Renewables electrical balance-of-systems (eBOS) business to a subsidiary of GameChange Energy Technologies Corp. for $70 million in cash, subject to customary post-closing adjustments.

Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that its Board of Directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be payable March 31, 2026, to shareholders of record as of March 17, 2026.

Dominion Energy, Inc. (NYSE: D), today announced unaudited net income determined in accordance with Generally Accepted Accounting Principles (GAAP, or reported earnings) for the three months ended Dec. 31, 2025, of $567 million ($0.65 per share) compared with net income of $134 million ($0.14 per share) for the same period in 2024, with net income of $3.0 billion ($3.45 per share) for the 12 months ended Dec. 31, 2025, compared with net income of $2.0 billion ($2.33 per share) for the same period in 2024.

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions.

Guala Closures, a global leader in specialty beverage and pharmaceutical closure solutions, has acquired Vinventions’ screwcap production business located in Rosarito, Mexico, expanding its manufacturing footprint in North America and strengthening its supply capabilities for the U.S. wine and spirits market.

Agreement between QLE’s South African subsidiary and Necsa related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba, with QLE’s objective to achieve market readiness for production of nuclear fuel

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences:

-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 -- 

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March: